Covid Vaccines Can Elicit a Distinct T Cell Dominant Immune Mediated Hepatitis

Long story short- Covid Jabs can give you Hepatitis

In a recent study published in the Journal of Hepatology, researchers reported that the coronavirus disease 2019 (COVID-19) vaccination could elicit a distinct T cell-dominant immune-mediated hepatitis.

Vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is critical to combat the COVID-19 pandemic. Recently, several reports have surfaced indicating autoimmune hepatitis (AIH)-like conditions post-COVID-19 vaccination, not observed during clinical trials. Liver injury has been observed with both vector- and messenger ribonucleic acid (mRNA)-based vaccines with a varying period of vaccination-to-symptom onset.

Autoimmune serological tests revealed mild hyperglobulinemia, antinuclear antibodies (ANA), and borderline positivity for anti-mitochondrial M2 antibody (AMA-M2) and anti-smooth muscle antibodies, while anti-liver kidney microsomal (LKM) antibody tests were negative. The liver biopsy revealed interface hepatitis with moderate lymphoplasmacytic infiltrate and lobular necrotic and apoptotic foci. These clinical findings were consistent with a probable AIH, and the treatment was 9 mg of budesonide/day. In the ensuing weeks, levels of liver enzymes dropped, and another relapse occurred after 39 days of therapy initiation, controlled by systemic steroids and ursodeoxycholic acid.


The researchers noted a slight increase in peripheral immunoglobulins and intrahepatic enrichment of plasma and B cells. Strikingly, cytotoxic CD8 T cells (CD38-expressing) were the most enriched to the extent that they were the most abundant immune cells in the liver.

These observations implicated T cells as the pathogenic cell type associated with the vaccination-related immune hepatitis as the novel AIH subtype. These findings indicated that vaccination with BNT162b2 might cause immune-mediated hepatitis by vaccine-elicited cellular immunity mechanisms.

5 replies on “Covid Vaccines Can Elicit a Distinct T Cell Dominant Immune Mediated Hepatitis”

Danish professor: mRNA vaccine study sends ‘danger signals.
A new Danish study reveals disparities in all-cause mortality between mRNA and adenovirus vaccines. The results raise some difficult questions about the unexpected effects of the most popular COVID vaccines. Freddie Sayers speaks to the study’s author Prof. Christine Stabell-Benn, from the University of Southern Denmark.

When she was asked if she would recommend Pfizer/Moderna if she had children in their 20’s, she said no! She also stated she would not recommend it for people over 50! What was interesting is what she found was Astrozeneca vax had a better all cause mortality profile. Interesting.

Latest from Geert Vanden Bossche
Why are breakthrough infections with Omicron anything but a blessing and why will re-vaccination of C-19 vaccinees with an updated S(Omicron)-based C-19 vaccine make things even worse?

On the other hand, elevated titers of non-neutralizing infection enhancing Abs shorten the duration of individual protection after breakthrough infection and increase the risk for a vaccinated individual to develop long-haul Covid. It follows that i) highly vaccinated populations are now paving the way for breeding variants that will not only be highly infectious but also highly virulent in vaccinees [1] and ii) that protection of vaccinees subsequent to breakthrough infection will only be of short duration while their susceptibility to long-haul Covid will dramatically increase.

None of this applies to non-vaccinated individuals as their recovery from symptomatic SC-2 disease

results in improved innate immunity that – thanks to the epigenetic mechanism of innate immune adaptation (training!) – will confer more effective sterilizing immunity upon future exposure and

generates anti-S Abs that efficiently neutralize the virus as these Abs are induced by the circulating variant (and not by the heterologous S protein of the Wuhan strain used in the vaccine) and will only have to deal with a low viral load because most (if not all!) of the viral inoculum from a new infection will be taken care of by the host’s improved first line of immune defense, which got trained thanks to its previous disease-fighting experience.

Leave a Reply